{"id":"W2053901787","doi":"10.1016/j.ahj.2013.12.024","title":"Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion","year":2014,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"St. Jude Medical; Daiichi-Sankyo; AstraZeneca; Bayer; Boehringer Ingelheim; Medtronic; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Medicine; Rivaroxaban; Atrial fibrillation; Cardioversion; Cardiology; Internal medicine; Clinical trial; Intensive care medicine; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04559223,0.003306143,0.004542921,0.001333042,0.002007676,0.002994609,0.002560196,0.004406154,0.01375453],"category_scores_gemma":[0.03795619,0.002782245,0.004926317,0.001107117,0.00492135,0.001882813,0.001706764,0.006240585,0.003089796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001585545,"about_ca_system_score_gemma":0.007603235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008614726,"about_ca_topic_score_gemma":0.001184349,"domain_scores_codex":[0.9772414,0.01447326,0.002323273,0.002840531,0.001996396,0.001125176],"domain_scores_gemma":[0.9874699,0.005225792,0.00192269,0.00204542,0.001458374,0.001877848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7786729,0.02342216,0.02149993,0.01003287,0.007241432,0.0007148918,0.00130814,0.003685019,0.00543233,0.05378424,0.01109934,0.08310667],"study_design_scores_gemma":[0.8079693,0.08249835,0.01915961,0.002353025,0.007491981,0.0005482942,0.0003076229,0.00497074,0.002077516,0.02120906,0.05110488,0.0003096937],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1012164,0.01082437,0.03174862,0.008990386,0.007792269,0.8174949,0.008645589,0.0002542811,0.01303315],"genre_scores_gemma":[0.1661959,0.002226112,0.04060899,0.007773394,0.003022102,0.7750086,0.00193867,0.0000471188,0.00317923],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.04559223,"threshold_uncertainty_score":0.2411177,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04239475961315793,"score_gpt":0.302401965416844,"score_spread":0.2600072058036861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}